Current developments of immunotherapy in the clinic

Current Opinion in Immunology

Volumn 16, Issue 2, 2004, Pages 130-136

  Antonia, Scott ^a   Mulé, James J ^a   Weber, Jeffrey S ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Complete response; CR; CTL; CTL antigen 4; CTLA 4; Cytotoxic T lymphocyte; GM CSF; Granulocyte macrophage colony stimulating factor; Heat shock protein; HLA; Hsp; Human leukocyte antigen; IFN; IL; Interferon; Interleukin; MAGE; MART 1; Melanoma antigen

Indexed keywords

ADENOVIRUS VECTOR; BCG VACCINE; CANCER VACCINE; CANVAXIN; CARCINOEMBRYONIC ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLT3 LIGAND; FREUND ADJUVANT; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 96; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELACINE; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN A1; MONOPHENOL MONOOXYGENASE; OLIGONUCLEOTIDE; PROTEIN ANTIBODY; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; RECOMBINANT PROTEIN; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; AUTOIMMUNE DISEASE; AUTOIMMUNE VITILIGO; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CLONE; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DIGESTIVE SYSTEM CANCER; DRUG RESEARCH; DRUG RESPONSE; EXPERIMENTAL MODEL; HUMAN; IMMUNOTOXICITY; LUNG CANCER; MELANOMA; METASTASIS; MOLECULAR DYNAMICS; NONHUMAN; OVARY CANCER; PANCREAS CANCER; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TUMOR REGRESSION; VITILIGO;

ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MELANOMA; NEOPLASMS; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 1542351347     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2004.01.012     Document Type: Review

References (68)

1. Hsueh E.C., Gupta R.K., Qi K., Morton D.L. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving ployvalent melanoma cell vaccine. J Clin Oncol. 16:1998;2913-2920.
2. Mitchell M.S. Cancer vaccines, a critical review-part I. Curr Opin Investig Drugs. 3:2002;140-149.
3. Sosman J.A., Unger J.M., Liu P.Y., Flaherty L.E., Park M.S., Kempf R.A., Thompson J.A., Terasaki P.I., Sondak V.K. Southwest Oncology Group. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol. 20:2002;2067-2075.
4. Sondak V.K., Liu P.Y., Tuthill R.J., Kempf R.A., Unger J.M., Sosman J.A., Thompson J.A., Weiss G.R., Redman B.G., Jakowatz J.G.et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol. 20:2002;2058-2066.
5. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R.C. Vaccination with irradiated tumor cells engineered to secrete GM-CSF stimulates potent, specific, and long lasting anti-tumor immunity. Proc Natl Acad Sci USA. 90:1993;3539-3543.
6. Soiffer R., Hodi F.S., Haluska F., Jung K., Gillessen S., Singer S., Tanabe K., Duda R., Mentzer S., Jaklitsch M.et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 21:2003;3343-3350.
7. Salgia R., Lynch T., Skarin A., Lucca J., Lynch C., Jung K., Hodi F.S., Jaklitsch M., Mentzer S., Swanson S.et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 21:2003;624-630.
8. Jaffee E.M., Hruban R.H., Biedrzycki B., Laheru D., Schepers K., Sauter P.R., Goemann M., Coleman J., Grochow L., Donehower R.C.et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 19:2001;145-156.
9. Belli F., Testori A., Rivoltini L., Maio M., Andreola G., Sertoli M.R., Gallino G., Piris A., Cattelan A., Lazzari I.et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol. 20:2002;4169-4180 This is the first evidence that heat shock proteins are immunogenic in humans and can induce anti-tumor responses.
10. Mazzaferro V., Coppa J., Carrabba M.G., Rivoltini L., Schiavo M., Regalia E., Mariani L., Camerini T., Marchiano A., Andreola S.et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res. 9:2003;3235-3245.
11. Marchand M., van Baren N., Weynants P., Brichard V., Dreno B., Tessier M.H., Rankin E., Parmiani G., Arienti F., Humblet Y.et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 80:1999;219-230.
12. Marchand M., Punt C.J., Aamdal S., Escudier B., Kruit W.H., Keilholz U., Hakansson L., van Baren N., Humblet Y., Mulders P.et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer. 39:2003;70-77.
13. Jager E., Ringhoffer M., Karbach J., Arand M., Oesch F., Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer. 66:1996;470-476.
14. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Dudley M.E., Schwarz S.L., Spiess P.J.et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 4:1998;321-327.
15. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., Restifo N.P., Haworth L.R., Seipp C.A., Freezer L.J.et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 100:2003;8372-8377 The establishment of a new paradigm for the association of clinical autoimmunity induced by a biological compound and anti-tumor response in melanoma.
16. Slingluff C.L. Jr., Petroni G.R., Yamshchikov G.V., Barnd D.L., Eastham S., Galavotti H., Patterson J.W., Deacon D.H., Hibbitts S., Teates D.et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 21:2003;4016-4026.
17. Bettinotti M.P., Panelli M.C., Ruppe E., Mocellin S., Phan G.Q., White D.E., Marincola F.M. Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702- associated epitope MAGE-A12:170-178. Int J Cancer. 105:2003;210-216.
18. Cebon J., Jager E., Shackleton M.J., Gibbs P., Davis I.D., Hopkins W., Gibbs S., Chen Q., Karbach J., Jackson H.et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun. 3:2003;7-17.
19. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D. Vaccination of melanoma patient s with peptide- or tumor-lysate pulsed dendritic cells. Nat Med. 4:1998;328-332.
20. Panelli M.C., Wunderlich J., Jeffries J., Wang E., Mixon A., Rosenberg S.A., Marincola F.M. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother. 23:2000;487-498.
21. Sadanaga N., Nagashima H., Mashino K., Tahara K., Yamaguchi H., Ohta M., Fujie T., Tanaka F., Inoue H., Takesako K.et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res. 7:2001;2277-2284.
22. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., Bender A., Maczek C., Schreiner D., von den Dreisch P.et al. Vaccination with Mage-3A1 peptide-pulsed mature monocyte-derived dendritic cells expands specific cytotoxic T-cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 190:1999;1669-1678.
23. Mackensen A., Herbst B., Chen J.L., Kohler G., Noppen C., Herr W., Spagnoli G.C., Cerundolo V., Lindemann A. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer. 86:2000;385-392.
24. Banchereau J., Palucka A.K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., Taquet S., Coquery S., Wittkowski K.M., Bhardwaj N.et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61:2001;6451-6458.
25. Fong L., Hou Y., Rivas A., Benike C., Yuen A., Fisher G.A., Davis M.M., Engleman E.G. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA. 98:2001;8809-8814.
26. Geiger J., Hutchinson R., Hohenkirk L., McKenna E., Chang A., Mulé J.J. Treatment of solid tumors in children with tumour-lysate- pulsed dendritic cells. Lancet. 356:2000;1163-1164.
27. Chang A.E., Redman B.G., Whitfield J.R., Nickoloff B.J., Braun T.M., Lee P.P., Geiger J.D., Mule J.J. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res. 8:2002;1021-1032.
28. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., Greenberg P.D. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 99:2002;16168-16173.
29. Dudley M.E., Wunderlich J.R., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R.M., Marincola F.M., Leitman S.F., Seipp C.A.et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 25:2002;243-251.
30. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M.et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:2002;850-854 This is the first demonstration that lymphoid depletion followed by adoptive cell transfer in the face of homeostatic lymphoid proliferation augment anti-tumor T-cell responses.
31. Mitchell M.S., Darrah D., Yeung D., Halpern S., Wallace A., Voland J., Jones V., Kan-Mitchell J. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol. 20:2002;1075-1086.
32. Overwijk W.W., Theoret M.R., Restifo N.P. The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci Am. 6(Suppl 1):2000;S76-S80.
33. Shimizu K., Fields R.C., Giedlin M., Mule J. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci USA. 96:1999;2268-2273.
34. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K.et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 8:2002;793-800.
35. Carter L., Fouser L.A., Jussif J., Fitz L., Deng B., Wood C.R., Collins M., Honjo T., Freeman G.J., Carreno B.M. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol. 32:2002;634-643.
36. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 3:2003;133-146.
37. Leonard J.P., Sherman M.L., Fisher G.L., Buchanan L.J., Larsen G., Atkins M.B., Sosman J.A., Dutcher J.P., Vogelzang N.J., Ryan J.L. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 90:1997;2541-2548.
38. Noguchi Y., Richards E.C., Chen Y.T., Old L.J. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA. 92:1995;2219-2223.
39. Fallarino F., Uyttenhove C., Boon T., Gajewski T.F. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. Int J Cancer. 80:1999;324-333.
40. Peterson A.C., Harlin H., Gajewski T.F. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol. 21:2003;2342-2348.
41. Morse M.A., Nair S., Fernandez-Casal M., Deng Y., St Peter M., Williams R., Hobeika A., Mosca P., Clay T., Cumming R.I.et al. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J Clin Oncol. 18:2000;3883-3893.
42. Rini B.I., Paintal A., Vogelzang N.J., Gajewski T.F., Stadler W.M. Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. J Immunother. 25:2002;269-277.
43. Disis M.L., Rinn K., Knutson K.L., Davis D., Caron D., dela Rosa C., Schiffman K. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood. 99:2002;2845-2850.
44. Grewal I.S., Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 16:1998;111-135.
45. Delamarre L., Holcombe H., Mellman I. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med. 198:2003;111-122.
46. Sotomayor E.M., Borrello I., Tubb E., Rattis F.M., Bien H., Lu Z., Fein S., Schoenberger S., Levitsky H.I. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med. 5:1999;780-787.
47. Brossart P., Zobywalski A., Grunebach F., Behnke L., Stuhler G., Reichardt V.L., Kanz L., Brugger W. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res. 60:2000;4485-4492.
48. Pirtskhalaishvili G., Shurin G.V., Esche C., Cai Q., Salup R.R., Bykovskaia S.N., Lotze M.T., Shurin M.R. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br J Cancer. 83:2000;506-513.
49. Esche C., Gambotto A., Satoh Y., Gerein V., Robbins P.D., Watkins S.C., Lotze M.T., Shurin M.R. CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. Eur J Immunol. 29:1999;2148-2155.
50. Dotti G., Savoldo B., Yotnda P., Rill D., Brenner M.K. Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells. Blood. 100:2002;200-207.
51. Vonderheide R.H., Dutcher J.P., Anderson J.E., Eckhardt S.G., Stephans K.F., Razvillas B., Garl S., Butine M.D., Perry V.P., Armitage R.J.et al. J Clin Oncol. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol. 19:2001;3280-3287.
52. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 20:2002;709-760.
53. Krieg A.M. CpG motifs: the active ingredient in bacterial extracts? Nat Med. 9:2003;831-835.
54. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A Toll-like receptor recognizes bacterial DNA. Nature. 408:2000;740-745.
55. Jakob T., Walker P.S., Krieg A.M., Udey M.C., Vogel J.C. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol. 161:1998;3042-3049.
56. Sparwasser T., Koch E.S., Vabulas R.M., Heeg K., Lipford G.B., Ellwart J.W., Wagner H. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol. 28:1998;2045-2054.
57. Hartmann G., Weiner G.J., Krieg A.M. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA. 96:1999;9305-9310.
58. Brunner C., Seiderer J., Schlamp A., Bidlingmaier M., Eigler A., Haimerl W., Lehr H.A., Krieg A.M., Hartmann G., Endres S. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol. 165:2000;6278-6286.
59. Sandler A.D., Chihara H., Kobayashi G., Zhu X., Miller M.A., Scott D.L., Krieg A.M. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res. 63:2003;394-399.
60. Rieger R., Kipps T.J. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Res. 63:2003;4128-4135.
61. Davila E., Kennedy R., Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 63:2003;3281-3288.
62. Stern B.V., Boehm B.O., Tary-Lehmann M. Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity. J Immunol. 168:2002;6099-6105.
63. Merad M., Sugie T., Engleman E.G., Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood. 99:2002;1676-1682.
64. Halperin S.A., Van Nest G., Smith B., Abtahi S., Whiley H., Eiden J.J. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine. 21:2003;2461-2467.
65. van Ojik H. Phase I/II study with CpG 7909 as adjuvant to vaccination with MAGE-3 protein in patients with MAGE-3 positive tumors. Ann Oncol. 13:2002;157.
66. Walunas T.L., Bluestone J.A. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1:1994;405-413.
67. Chambers C.A., Krummel M.F., Boitel B., Hurwitz A., Sullivan T.J., Fournier S., Cassell D., Brunner M., Allison J.P. The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev. 153:1996;27-46.
68. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., Davis T., Henry-Spires R., MacRae S., Willman A.et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 100:2003;4712-4717 This is the first clinical demonstration that CTLA-4 blockade can elicit measurable immunological effects in melanoma patients.